What is SigmaGraft?
SigmaGraft Biomaterials operates at the intersection of advanced material science and clinical application, specializing in the development of high-performance solutions for the dental and orthopedic markets. By engineering sophisticated allografts, bone substitutes, and resorbable membranes, the company addresses critical needs in surgical recovery and tissue regeneration. Their business model is anchored in deep collaboration with clinical researchers, ensuring that their product pipeline remains at the forefront of medical efficacy. This focus on quality and patient-centric outcomes has established SigmaGraft as a pivotal player in the biomaterials landscape, providing essential tools that facilitate complex orthopedic and dental procedures.
How much funding has SigmaGraft raised?
SigmaGraft has raised a total of $381K across 2 funding rounds:
Debt
$150K
Debt
$231K
Debt (2020): $150K with participation from PPP
Debt (2021): $231K led by PPP
Key Investors in SigmaGraft
PPP
Public-Private Partnership
What's next for SigmaGraft?
With the recent influx of capital, SigmaGraft is well-positioned to scale its manufacturing capabilities and accelerate its research and development initiatives. The company is expected to leverage this financial backing to deepen its penetration into global markets, potentially expanding its portfolio of wound dressings and regenerative products. As the firm transitions through this late-stage growth phase, the strategic deployment of these funds will likely focus on optimizing supply chain resilience and fostering new partnerships with academic institutions to maintain its competitive edge in the rapidly evolving medical device industry.
See full SigmaGraft company page
